Denosumab-induced osteonecrosis of the jaw: a case report
-
Rubio Ramírez, Lourdes [1] ; Serrano Sánchez-Rey, Mª Cristina [1] ; López-Pintor Muñoz, Rosa Mª [1] ; De Arriba de la Fuente, Lorenzo [1]
-
[1] Universidad Complutense de Madrid
Universidad Complutense de Madrid
Madrid, España
-
- Localización: Científica dental: Revista científica de formación continuada, ISSN 1697-6398, ISSN-e 1697-641X, Vol. 14, Nº. Extra 4 (Versión en inglés de los trabajos ganadores y los segundos clasificados de los premios de la revista), 2017, págs. 48-54
- Idioma: inglés
- Enlaces
-
Resumen
Osteonecrosis of the jaw (ONJ) induced by antiresorptive drugs, mainly bisphosphonates (BP), is widely described in the scientific literature. In recent years, there have been reports of ONJ induced by other antiresorptive drugs such as Denosumab, Bevacizumab and Sunitinib used in cancer patients. Denosumab is a monoclonal antibody used in the treatment of osteoporosis and in the prevention of fracturesfollowing treatment ofsome types of cancer.
In this article, we present the case of a patient who developed ONJ. The patient had periodontal disease and osteoporosis, which had been treated for years with Alendronate (oral bisphosphonate) and currentlywithDenosumab. In addition,she had a poorly adapted removable prosthesis. This paper discusses the risk of ONJ associated with such drugs, and the possible influence of certain localfactors on the occurrence of this condition, as well as the preventive and therapeutic measures thatshould be adopted in these cases.
